Saxenda vs Zepbound: How They Compare

Saxenda and Zepbound are both FDA-approved, prescription-only injectable medicines for chronic weight management — but they belong to different generations of the same drug class, and the gap between them is large. Saxenda is daily liraglutide, a single-receptor GLP-1 agonist approved in 2014. Zepbound is once-weekly tirzepatide, a dual GIP/GLP-1 agonist approved in 2023. They have never been tested head-to-head in a single trial, so an honest comparison has to read across separate studies — but those studies point clearly in one direction on average effect.

The headline difference: weekly dual agonist vs daily single agonist

Zepbound's active ingredient, tirzepatide, activates two incretin receptors — GIP and GLP-1 — with one molecule, and is injected once weekly¹. Saxenda's active ingredient, liraglutide, activates only the GLP-1 receptor and must be injected once daily because of its shorter duration of action². Both are approved as additions to a reduced-calorie diet and increased physical activity for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition; Saxenda is also approved down to age 12, and Zepbound carries an additional approval for moderate-to-severe obstructive sleep apnea in adults with obesity¹².

So the practical contrast is two-fold: how often you inject (weekly vs daily), and how much weight the average person loses. On both counts the newer drug has the edge.

Average weight loss: reading across the trials

There is no Saxenda-vs-Zepbound trial, so the fair approach is to compare each drug against placebo in its own pivotal obesity study and keep the populations in mind.

For liraglutide (Saxenda), the pivotal SCALE Obesity and Prediabetes trial randomized adults with obesity (or overweight with comorbidities) to liraglutide 3.0 mg daily or placebo for 56 weeks. The liraglutide group lost about 8% of body weight versus about 2.6% on placebo — a roughly 5–6 percentage-point placebo-subtracted effect³.

For tirzepatide (Zepbound), the pivotal SURMOUNT-1 trial randomized adults with obesity (without diabetes) to tirzepatide or placebo for 72 weeks. At the top 15 mg dose, mean weight reduction reached roughly 21%, with about 15% even at the lowest 5 mg dose⁴. Our Zepbound results: how much weight explainer breaks those trial averages down dose by dose.

The cleanest indirect signal comes from STEP 8, a randomized trial that pitted once-weekly semaglutide against daily liraglutide 3.0 mg in the same study. Liraglutide produced about 6.4% mean weight loss — and semaglutide nearly doubled it⁵. Tirzepatide, in turn, beat maximum-dose semaglutide head-to-head in SURMOUNT-5⁶. Chaining those comparisons honestly — liraglutide < semaglutide < tirzepatide — places Saxenda at the lower end and Zepbound at the upper end of the modern weight-management ladder. A 2025 umbrella review of GLP-1-class trials reaches the same broad ordering⁷.

The honest caveat: these are different trials, different durations, and different populations, so the exact numbers are not directly subtractable. But the direction is consistent and large — tirzepatide's average weight loss is meaningfully greater than liraglutide's. What no trial average tells you is which drug a specific person will tolerate or respond to best; some people do well on liraglutide, and individual results always vary.

Dosing: daily vs weekly titration

Both drugs are started low and titrated up to limit nausea. Saxenda escalates weekly over about five weeks — 0.6, 1.2, 1.8, 2.4, then the 3.0 mg daily maintenance dose². Zepbound starts at 2.5 mg once weekly and increases in 2.5 mg steps no sooner than every four weeks toward maintenance doses of 5, 10, or 15 mg weekly¹. The most obvious quality-of-life difference is frequency: Saxenda is 7 injections a week, Zepbound is one. For the full Zepbound ladder, see our tirzepatide dosage chart and most effective Zepbound dose guides.

Side effects: the same class profile

Because both act on GLP-1, they share the same dominant side-effect category: gastrointestinal events — nausea, diarrhea, constipation, vomiting — that are generally mild to moderate, worst during dose escalation, and the leading reason people stop¹². Both labels carry a boxed warning about the risk of thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2¹². Both also warn about pancreatitis, gallbladder disease, and acute kidney injury from dehydration. The class is similar enough that switching does not escape the GI tradeoff — it is managed the same way for both: titrate slowly. Our Zepbound side effects guide covers the tirzepatide profile in detail.

Durability: weight returns when either drug stops

Neither drug is a one-time fix. Tirzepatide's SURMOUNT-4 trial showed that people who stopped the drug regained a substantial share of lost weight, while those who continued kept losing — evidence that the effect depends on ongoing treatment⁸. The same regain pattern is well documented across the GLP-1 class⁷. Whichever drug is used, maintenance generally means continued use, not a finite course. We cover that reality in stopping tirzepatide and the Zepbound maintenance dose guide.

Cost

Both are expensive brand-name drugs without a generic. List prices for both run well over $1,000 per month before insurance, and out-of-pocket cost depends heavily on coverage and manufacturer savings programs. Eli Lilly sells Zepbound in lower-cost single-dose vials through a self-pay channel, which has shifted the practical price comparison somewhat, but neither drug is cheap. Coverage for weight-management indications is inconsistent across plans. We walk through the real numbers in Zepbound cost and savings and does insurance cover Zepbound — and the same coverage hurdles generally apply to Saxenda.

The honest verdict

Saxenda and Zepbound are both legitimate, FDA-approved weight-management drugs, but they are not equivalent. Zepbound (weekly tirzepatide) delivers substantially greater average weight loss across the trial record, is injected once a week instead of daily, and adds a sleep-apnea indication — while Saxenda (daily liraglutide) is the older, lower-efficacy, more frequently injected option that nonetheless has a long safety record and broader age approval. They share the same GLP-1 side-effect profile, the same boxed thyroid warning, the same regain-on-stopping reality, and similarly high cost. "Greater on average in trials" is not the same as "right for you" — that decision belongs with a qualified prescriber. For the full evidence base, see our tirzepatide evidence guide, compare the providers in our best tirzepatide overview, and for the other major matchup read tirzepatide vs semaglutide.